North America DNA Sequencing Market Size, Share and Trends 2026 to 2035

The North America DNA sequencing market size accounted for USD 7.5 billion in 2025 and is predicted to touch around USD 27.56 billion by 2035, growing at a CAGR of 13.9% from 2026 to 2035. The market is mainly fueled by the growing use of precision medicine, significant investments from both federal and private sectors in genomics research, and a rise in cancer and rare genetic diseases.

North America DNA Sequencing Market Statical Scope

The market is crucial as it holds the largest share globally, leads advancements in precision medicine, and has a strong biotechnology infrastructure. It serves as the key center for genomic innovation and commercial use. There is a rapid adoption of genetic profiling to focus on specific cancer treatments and therapies. The area has a high concentration of leading research institutions, clinical labs, and biopharmaceutical companies.

There is a broad reliance on Next-Generation Sequencing (NGS) for quick and accurate diagnoses. Significant private and federal funding, including efforts from the National Institutes of Health (NIH), boosts large-scale genomic initiatives. It is home to major industry leaders like Illumina and Thermo Fisher Scientific, which set global technology standards. The market benefits from ongoing revenue generated by high-volume sequencing processes and lab testing supplies.

North America DNA Sequencing Market, By Product, 2025 (%)

• Instruments - The instruments segment, with a share of 25.80% in 2025, plays a key role in the North America DNA sequencing market as it supplies the essential hardware for high-throughput Next-Generation Sequencing (NGS), facilitates quick clinical diagnostics, and fosters innovation in personalized medicine.
• Consumables - The consumables segment, with a share of 54.70% in 2025, leads the North America DNA Sequencing Market as it generates ongoing revenue through necessary daily use, supports high-throughput clinical and research processes, and is fundamental to the region's extensive genomics active American DNA sequencing market by supplying essential hardware for high-throughput Next-Generation Sequencing (NGS), facilitating rapid clinical diagnostics.
• Services - The services segment, with a share of 19.50% in 2025, is important in the North America DNA sequencing market as it shows the fastest growth by offering essential bioinformatics, minimizing the need for expensive in-house equipment, and helping precision medicine.

North America DNA Sequencing Market, By Technology, 2025 (%)

• Third Generation DNA Sequencing - The Third-Generation DNA Sequencing (TGS) segment, with a share of 22.40% in 2025, is significant in the North America DNA Sequencing Market due to its long-read capabilities, acceleration of precision medicine, and robust regional infrastructure. It allows real-time tracking of single molecules, addresses complex structural genomic variants, and promotes advancements in oncology.
• Next-Generation Sequencing - The Next-Generation Sequencing (NGS) segment, with a share of 63.80% in 2025, leads the North America DNA sequencing market due to its high throughput, quick turnaround, and essential role in precision medicine. It holds a significant market share by enabling advanced oncology profiling, rare disease detection, and affordable clinical diagnostics.

North America DNA Sequencing Market, By Application, 2025 (%)

• Clinical Investigation – The clinical investigation, with a share of 26.10% in 2025, is crucial in the North America DNA sequencing market as it promotes personalized medicine, allows for targeted cancer profiling, and takes advantage of robust insurance reimbursement systems. This segment transforms genomic sequencing from fundamental research into routine patient care.
• Oncology - The oncology sector, with a share of 29.40% in 2025, plays a crucial role in the North American DNA sequencing market due to high cancer prevalence, a significant move towards precision medicine, and substantial investments in genomics. It dominates application segments by obtaining the largest revenue share through targeted tumor profiling and companion diagnostics.

North America DNA Sequencing Market, By End-Use, 2025 (%)

• Clinical Research - The clinical research sector, with a share of 28.70% in 2025, leads the North American DNA sequencing market as it promotes precision medicine, speeds up targeted oncology treatments, and improves clinical trial designs. It represents a significant part of regional genomic adoption, supported by strong institutional funding and advanced healthcare systems.
• Academic Research - The academic research sector, with a share of 21.90% in 2025, is key to the North American DNA sequencing market as it fosters foundational genomic innovation, attracts large government and institutional funding, and has led the way in adopting high-throughput next-generation sequencing (NGS).

Competitive Landscape

The North American DNA sequencing market is centered around a few key hardware and consumable suppliers, primarily Illumina, Thermo Fisher Scientific, and Pacific Biosciences. The region's growth is driven by clinical oncology applications, precision medicine, and a large number of installed instruments.

• Illumina, Inc. holds the largest market share with its sequencing-by-synthesis systems. Their products range from ultra-high-throughput systems like the NovaSeq family to benchtop models (MiSeq, NextSeq) and clinical assay kits.
• Thermo Fisher Scientific is a major player in clinical and targeted sequencing, offering Ion Torrent sequencing systems (Ion GeneStudio S5) and RapidHIT platforms for quick human identification and targeted oncology.
• Pacific Biosciences (PacBio) focuses on high-accuracy long-read sequencing technology, with products like the Sequel and Revio systems that use HiFi sequencing chemistry for analyzing complex structural variants.
• Oxford Nanopore Technologies offers scalable, real-time nanopore-based sequencing, with products ranging from portable devices (MinION) to high-throughput benchtop stations (PromethION).
• Element Biosciences is a disruptive player in benchtop economics, with its AVITI system aimed at reducing per-gigabase running costs for standard genomic workflows.
• Agilent Technologies provides specialized target enrichment solutions, including SureSelect target enrichment panels and quality analysis tools used in NGS workflows.
• QIAGEN leads in the sample preparation area, offering QIAseq library preparation kits, automated extraction instruments (QIAcube), and specialized bioinformatics analysis pipelines.

Segments Covered in the Report

By Product

• Instruments
• Consumables
• Services

By Technology

• Next-Generation Sequencing (NGS)
• Third Generation DNA Sequencing (TGS)
• Sanger Sequencing

By Application

• Oncology
• Clinical Investigation
• Reproductive Health
• Forensics & Agrigenomics
• HLA Typing
• Others

By End-Use

• Clinical Research
• Biotechnology & Pharmaceutical Companies
• Academic Research
• Hospitals & Clinics
• Others